David B. Solit

Oncology
353 E 68th St
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 336 publications

Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.

Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.

Journal: Nature medicine
Published: September 02, 2026

Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.

Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.

Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026

Prevalence of Germline Pathogenic RET Variants in a Pan-Cancer Patient Population.

Prevalence of Germline Pathogenic RET Variants in a Pan-Cancer Patient Population.

Journal: JCO precision oncology
Published: May 22, 2026

A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.

A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 24, 2026

Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma.

Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma.

Journal: JCO precision oncology
Published: April 22, 2026

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Journal: Cancer cell
Published: April 19, 2026

Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.

Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.

Journal: medRxiv : the preprint server for health sciences
Published: April 03, 2026

Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.

Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.

Journal: JCO precision oncology
Published: March 18, 2026

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 29, 2026

Comprehensive clinical and genomic analysis of early onset cancer of the bladder and upper urinary tract.

Comprehensive clinical and genomic analysis of early onset cancer of the bladder and upper urinary tract.

Journal: Journal of the National Cancer Institute
Published: December 22, 2025

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 13, 2025

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.

Journal: Cancer cell
Published: September 18, 2025
Showing 1-12 of 336

Last Updated: 09/26/2026